By Fineline Cube 
UK-headquartered Chromatin Bioscience has entered into a collaboration with Japan-based Astellas Pharma Inc. (TYO: 4503) to design cell-selective synthetic promoters aligned with Astellas’ target profile. The partnership leverages Chromatin’s proprietary chromatinLENS platform to achieve highly precise and durable gene expression in specific cell types, marking a significant step forward in gene therapy innovation.
Collaboration Objectives
The collaboration focuses on utilizing the chromatinLENS platform to identify gene regulatory elements from the dark genome and design synthetic promoters tailored to Astellas’ specific requirements. These promoters are expected to enable precise control over gene expression, enhancing the efficacy and safety of therapeutic applications.
ChromatinLENS Platform: Broad Applications
The chromatinLENS platform is a versatile tool applicable across multiple industries, including therapeutics, agritech, industrial biotechnology, and bioprocessing. Its ability to identify and design gene regulatory elements from underutilized genomic regions offers unprecedented opportunities for innovation in gene-based technologies.-Fineline Info & Tech